PubMed Health⌕ Search

Biomedical subjects

S B Patten

Publications and source records attributed to S B Patten.

At least 55 records · Page 3Linked to original sources

Drug-induced depression.

BACKGROUND: Certain drugs may contribute to the etiology of depressive symptoms and depressive disorders. The objective of this review is to critically appraise the literature concerned with these potential etiological associations. METHOD: The review was based on papers uncovered in electronic literature searches using Medline, Psychlit and Psychological Abstracts. Statistical power calculations were used to assist in the interpretation of negative results. RESULTS: A large number of publications were uncovered, but most of these were case reports. There were relatively few empirical studies. Corticosteroids, certain calcium channel blockers and digoxin have been associated with depression by replicated, well conducted studies. Psychostimulant withdrawal is also associated with prominent depressive symptoms. Preliminary evidence suggests that antihyperlipidemic agents, angiotensin converting enzyme inhibitors, sedative hypnotics, psychostimulants and certain hormonal agents may also cause depression. Despite an extensive literature, the potential association between beta-blockers and depressive symptoms remains controversial. There is no substantial evidence that l-dopa or histamine-2-receptor blockers cause depression and the literature is relatively conclusive in determining that thiazide diuretics are not associated with depressive symptoms. CONCLUSIONS: A small, but growing, literature confirms that certain drug exposures can contribute to the biopsychosocial etiology of depressive symptoms and disorders. Current beliefs and diagnostic conventions classify drug-induced depression into a distinct category (Substance-Induced Mood Disorder): but this approach is not specifically supported by the existing literature.

Depression↗

Depression in multiple sclerosis.

BACKGROUND: An association between multiple sclerosis (MS) and depression has been recognized for several decades and has attracted considerable attention in research. However, there are considerable gaps in the current state of knowledge. In this review, the literature concerned with: (1) the burden of depression in MS; (2) the etiology of depression in MS, and (3) the treatment of depression in MS are critically examined. METHOD: The literature review utilized Medline (1966-1996), and was supplemented by citations extracted from the papers originally uncovered. RESULTS: Numerous studies have identified elevated depressive symptom scores in MS patients relative to nonclinical and (some) clinical control groups. Furthermore, studies of depressive disorders have clearly documented elevated prevalence rates in MS samples. The literature does not identify any specific pattern of neurological involvement as being consistently associated with depressive symptoms or disorders. Psychosocial risk factors contribute to the etiology of depression in MS, but the relative importance of various risk factors is yet to be determined. A single randomized controlled clinical trial, and additional anecdotal evidence, suggests that antidepressant pharmacotherapy is effective for depressive disorders in MS. CONCLUSIONS: Future epidemiological studies should not restrict their evaluation of risk factors to those specific factors that are closely related to the disease process. In particular, future researchers should resist the temptation to focus too exclusively on neuropathology. Biological, psychological and social risk factors are all potentially important. Additional empirical efforts to refine the various treatment approaches would be a welcome addition to this literature.

Antidepressive Agents↗

The incidence of delirium in psychiatric inpatient units.

OBJECTIVES: To estimate prospectively the incidence of delirium in psychiatric inpatients and to identify risk factors for delirium in this population. METHOD: The subjects were nondelirious patients newly admitted to the Calgary General Hospital. The Delirium Symptom Interview (DSI), the Confusion Assessment Method (CAM), and the Mini-Mental State Examination (MMSE) were used to identify incident cases of delirium. In order to evaluate the potential impact of selection bias, we conducted a supplementary analysis using record linkage to an electronic administrative data base with coverage of the target population. RESULTS: Of 420 admissions to the hospital, 401 subjects provided informed consent and were not delirious at the time of admission. There were 9 incident cases of delirium. The cumulative incidence rate was, therefore, 2.14 per 100 admissions. The record linkage analysis did not uncover evidence of selection bias. Delirium was associated with a significantly increased length of stay in hospital. CONCLUSIONS: Delirium is an uncommon incident event in the psychiatric inpatient population. The incidence rate reported here may be useful as a benchmark for the identification of excessive rates in other inpatient settings. Since delirium is sometimes related to modifiable therapeutic factors, an excessive rate should prompt a search for its causes.

Adolescent↗

Performance of the Composite International Diagnostic Interview Short Form for major depression in community and clinical samples.

The CIDI Short Form is a brief survey instrument designed to identify episodes of major depression. The instrument was developed for inclusion in the US National Health Interview Survey, but has also been used in the Canadian National Population Health Survey (NPHS). In this study, data deriving from use of the CIDI Short Form in the NPHS are compared to published data from the Mental Health Supplement of the Ontario Health Survey, which utilized a fully validated structured interview: the Composite International Diagnostic Interview (CIDI). In an additional analysis, the sensitivity and specificity of the Short Form were evaluated in relation to the full CIDI mood disorders section in a clinical sample of 122 psychiatric in-patients. Relative to published data from the Ontario Health Survey, application of the CIDI Short Form in the NPHS resulted in an overestimation of major depression prevalence by approximately 50%. In the clinical sample, the CIDI Short Form was highly sensitive (98.4%), but not highly specific (72.7%). Active medical conditions, substance use disorders and dysthymia were frequently observed among subjects with false positive CIDI Short Form ratings. The CIDI Short Form appears to overestimate the 12-month period prevalence of major depression when it is applied in community samples. Since the Short Form does not make exclusions for organically induced symptoms, it is probable that some subjects with depressive symptoms secondary to physical illnesses and/or drug exposures score above the instrument's threshold, perhaps leading to an elevation in period prevalence rates.

Adolescent↗

New evidence on benzodiazepine use and falls: the time factor.

The objectives of this prospective study were to calculate incidence rates for fall-related hospitalization, to compare the effect of risk factors among benzodiazepine (BZD) users and unexposed controls, and to examine variations in risks according to length of time following a BZD prescription. Data were derived from Saskatchewan Health linked data bases, leading to information on 468 hospitalizations for injury due to falls among a study population of 321422. Incidence rates per 10000 within 28 days of the prescription fill date were 26.2, 12.1 and 9.0 for BZD sedative users, BZD tranquillizer users and for unexposed controls, respectively. Incidence rates increased with age, and were higher for women than for men. Results from multivariate logistic regression models also showed a greater risk of falling for BZD users but the odds ratio was higher for men than for women. A history of treatment for alcohol abuse was a very strong risk factor for falls among both men (odds ratio, 10.7) and women (odds ratio, 4.3). The highest risk of serious injury due to falls was within 15 days of filling the prescription, with an odds ratio of 3.6 for BZD sedatives and 2.6 for BZD tranquillizers. Risk decreased with further increase of time after the BZD fill date. For the individual BZD, flurazepam and triazolam showed the highest increase in risk with odds ratios of 3.4 and 2.7, respectively, while oxazepam, lorazepam and diazepam showed odds ratios of 2.2, 2.0 and 1.8 (all odds ratios mentioned are statistically significant at p < 0.05).

Accidental Falls↗

Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population.

OBJECTIVE: Certain medications used in cardiovascular therapeutics may contribute to the etiology of substance-induced mood disorders. These medications include digoxin, angiotensin converting enzyme (ACE) inhibitors, beta-blockers, and calcium channel blockers. The objective of this study was to evaluate associations between these drugs and clinical diagnoses of depressive disorders in a population of hospitalized patients. METHOD: Two case-control studies were conducted. For each study, subjects were selected from a health records data base maintained at the Calgary General Hospital. Selection of subjects in the first study was restricted to those receiving a discharge diagnosis of congestive heart failure and in the second study to subjects receiving a discharge diagnosis of hypertension. In each of these 2 studies, a single case group was selected along with 2 control groups: a psychiatric control group consisting of subjects receiving a psychiatric diagnosis other than a depressive disorder and a nonpsychiatric control group receiving no psychiatric diagnoses. Drug exposures and other variables were recorded from a chart review. RESULTS: Exposures to digoxin, beta-blockers, and calcium channel blockers were not associated with depressive diagnoses. An association was observed, however, for ACE inhibitors. An elevated odds ratio (OR) was observed in each case-control study and was stronger in female subjects and subjects over the age of 65. CONCLUSIONS: This is the first reported epidemiological evidence of an association between ACE inhibitors and depressive disorders. The design of this study does not permit a determination of whether the observed association was causal. Additional studies are needed.

Adult↗

Depressive symptoms attributable to medication exposure in a medical inpatient population.

OBJECTIVE: Exposure to certain drugs-angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers, corticosteroids. H2 blockers, and sedative hypnotics-may be associated with an increased risk of depression. These drugs are commonly used in inpatient medical therapeutics. Since population attributable risk (PAR) is generally related both to strength of association and to the frequency of exposure to a risk factor, the PAR of depressive symptoms associated with these drug exposures is potentially high. The objective of this study was to estimate the depressive symptoms population attributable risk percent (PAR%) in a medical inpatient population. METHODS: A prospective cohort design was used in this study. Nondepressed, nondrug-exposed subjects (N = 178) were selected from a series of 369 newly admitted medical inpatients at the Calgary General Hospital. Eighty-six of these 178 subjects were prescribed one of the drugs in question, forming an exposed cohort. The remaining subjects formed a nonexposed cohort. Depressive symptoms and associated psychosocial variables were measured in both subgroups during the hospital stay. RESULTS: Seventeen of the 86 exposed subjects and 5 of the 92 nonexposed subjects developed incident depressive symptoms during their stay in hospital. The PAR% associated with drug exposure (56.0%) exceeded that associated with poverty (17.9%) or unemployment (21.7%). CONCLUSIONS: Drug exposures may have a sizeable impact on the incidence of depressive symptoms in medical inpatient populations.

Alberta↗

Self-reported depressive symptoms following treatment with corticosteroids and sedative-hypnotics.

OBJECTIVE: To evaluate associations between exposure to corticosteroids or sedative-hypnotic medications and incident self-reported depressive symptoms in medical inpatients. METHOD: The study utilized a prospective cohort design, focusing on acute depressive symptoms developing soon after medication exposure. The incidence of self-reported depressive symptoms was evaluated using a modified version of the Center for Epidemiological Studies Depression Rating Scale (CES-D). The incidence of depressive symptoms in subjects newly exposed to corticosteroids and sedative-hypnotics was compared to that of a nonexposed comparison cohort. RESULTS: The incidence of self-reported depressive symptoms was elevated in subjects newly exposed to corticosteroids (Risk Ratio = 3.10), although the association did not attain statistical significance (p = .07). The risk ratio for sedative-hypnotic exposure was 4.18, a statistically significant finding (p = .02). As expected, incident self-reported depressive symptoms were also associated with several psychosocial variables. However, the data did not suggest that the observed associations between drug exposures and depressive symptoms were due to confounding by psychosocial or illness-related variables.

Adrenal Cortex Hormones↗

Self-reported depressive symptoms in association with medication exposures among medical inpatients: a cross-sectional study.

OBJECTIVE: To evaluate associations between exposure to three classes of medications (angiotensin converting enzyme inhibitors, calcium channel blockers, and corticosteroids) and self-reported depressive symptoms. METHOD: The study utilised a cross-sectional study design in a sample of medical inpatients. RESULTS: Associations between self-reported depressive symptoms and exposure to angiotensin converting enzyme inhibitors or calcium channel blockers were not observed. However, an association between self-reported depressive symptoms and corticosteroid exposure was identified. The association was strongest in subjects reporting a past history of depression or a family history of depression. The strength of the corticosteroid-depressive symptom association was comparable with that of associations observed for age, poverty and psychosocial stress. CONCLUSIONS: Depressive symptoms among medical inpatients have a biopsychosocial etiology. Corticosteroid exposure may be a biological risk factor for depressive symptoms in this population.

Adolescent↗

A case-control study of corticosteroid exposure as a risk factor for clinically-diagnosed depressive disorders in a hospitalized population.

OBJECTIVE: Depressive symptoms may be a side effect of exogenous corticosteroids. However, the literature does not confirm that corticosteroid exposure is associated with the occurrence of depressive disorders. The objective of this study was to determine whether or not corticosteroid exposures are associated with clinical diagnoses of depressive disorders in hospitalized patients. METHOD: The study used a case-control design. Cases and 2 control groups were selected from a health records case summary database maintained at the Calgary General Hospital. Additional data were collected by chart review. RESULTS: The analysis reproduced associations between depressive diagnoses and several psychosocial and biological risk factors. However, the data did not suggest that corticosteroids were associated with an elevated risk of depressive diagnoses. In fact, odds ratios for corticosteroid exposure were less than 1, consistent with a protective effect. CONCLUSIONS: Although corticosteroids may produce depressive symptoms as a side effect, corticosteroid exposures are not associated with an elevated risk of clinically diagnosed depressive disorders in hospitalized patients. There are several possible explanations for this. Depressive syndromes associated with corticosteroid exposure may not clinically resemble depressive disorders, and may not warrant a diagnosis of a depressive disorder. Alternatively, clinicians may not identify and formally diagnose depressive disorders caused by corticosteroids.

Adrenal Cortex Hormones↗

Drug-induced depression. Incidence, avoidance and management.

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), drug-induced depression may be classified as an Organic Mood Syndrome, Depressed Type. Unfortunately, the DSM-III-R diagnostic criteria are not sufficiently precise for application in research, and studies of drug-induced depression have rarely utilised these criteria. Research concerned with drug-induced depression is characterised by a number of methodological complications. These include differing definitions of depression, including depression defined as a symptom, a syndrome, or by diagnostic criteria for a specific mental disorder. In addition, patients undergoing pharmacological treatments for medical illnesses are typically exposed to considerable psychosocial stress due to the suffering and disability associated with illness. These psychosocial factors may in themselves precipitate episodes of depression. Due to these complicating factors, sophisticated study designs are required to confirm an aetiological role for medications as risk factors for depression. Unfortunately, adequate studies have rarely been conducted, and much of the literature consists of case reports and clinical observations. Consequently, clinicians are frequently required to make clinical judgements about the aetiology of patients' depressive symptoms in the absence of definitive scientific information about the role of drugs. Nevertheless, a knowledge of the relevant literature will assist clinicians in making reasoned judgements about the aetiology, prevention and management of these disorders.

Adrenal Cortex Hormones↗

Neuropsychiatric adverse drug reactions: passive reports to Health and Welfare Canada's adverse drug reaction database (1965-present).

OBJECTIVE: Since 1965, Health and Welfare Canada has operated an adverse drug reaction (ADR) program. The program accepts spontaneous reports of adverse drug reactions, and maintains an ADR database. The purpose of this article is to summarize the Psychiatric ADRs reported to this database since 1965. The nature of the information prohibits its use in the evaluation of epidemiological hypotheses about the etiology of drug-induced mental disorders. However, in an exploratory sense, the contents of the database may contribute to the development of epidemiological hypotheses about the etiology of drug-induced mental disorders. Of particular interest are areas of apparent contradiction between the contents of the database and the clinical literature. METHODS: The database was searched for reports of ADRs to a group of drugs which have been frequently implicated in causing psychiatric toxicity. All reports characterized as "psychiatric disorders" were down-loaded from the database for the analysis (n = 1822). The reports were further classified into nine categories according to the type of psychiatric symptoms described. RESULTS: There were several reports of hallucinations caused by methyldopa, and also several reports of benzodiazepine-induced hallucinations and encephalopathy. These reactions have not been described in the literature. Also, there were few reports of digoxin-induced organic depression, and an absence of reports of organic mania induced by H-2 blockers, despite descriptions of these sorts of reactions in the clinical literature. CONCLUSIONS: Further research is needed to define the neuropsychiatric toxicity associated with medical drugs. Clinicians must continue to consider the potential role of medications in the etiology of psychiatric symptoms.

Adverse Drug Reaction Reporting Systems↗

A clinical evaluation of the Neurobehavioral Cognitive Status Examination in a general psychiatric inpatient population.

The Neurobehavioral Cognitive Status Examination (NCSE) is a structured test of cognitive functioning. The NCSE assesses a broader range of cognitive functioning than the Mini-Mental State Examination (MMSE), but remains brief enough to be administered at the bedside in clinical settings. The purpose of this study was to assess the sensitivity, specificity, predictive value and reliability of the NCSE as a clinical case-finding instrument for DSM-III-R defined organic mental disorders in psychiatric inpatients. Validity was assessed by comparing the results of the test (interpreted as "pass" or "fail") to a blind clinical assessment by an experienced psychiatrist. The NCSE was found to have superior sensitivity to the MMSE (83% versus 43%), but inferior specificity (47% versus 97%). The low specificity resulted in a positive predictive value of only 24%. The NCSE had good test-retest reliability (Kappa = .69), but the inter-rater reliability was not as good (Kappa = 0.57). The NCSE was too non-specific to be used as a case-finding instrument for organic mental disorders. In conclusion, although clinicians may find the NCSE to be a valuable instrument for the assessment of cognitive function, it cannot be used as a screening or case-finding instrument for organic disorders among psychiatric inpatients.

Adult↗

Clinical interpretation of the mini-mental state.

The Mini-Mental Status Examination (MMSE) is a brief, structured test of cognitive function. The test is often used as a screening or case-finding instrument for the detection of organic mental disorders or cognitive impairment. However, many clinicians incorporate the MMSE into their clinical mental status examination. In both contexts, cutoff scores are often utilized to interpret the results, with scores below the cutoff being interpreted as evidence of cognitive dysfunction, and scores above the cutoff being interpreted as evidence against such dysfunction. However, when the test is done as part of a mental status examination, the application of a cutoff score fails to take account of prior clinical information, which is critical to the interpretation of all diagnostic tests. In this paper, an alternative approach to interpretation is proposed. In the proposed method, guidelines for interpretation are based on the probability of being free of organic disease at each potential score. Scores are interpreted in terms of their consistency or inconsistency with a prior diagnostic impression. This takes prior clinical information and clinical judgment into account. Although different from the traditional way of interpreting the MMSE, the proposed method can be implemented on an intuitive level and does not require mathematical calculations, which are inconvenient at the bedside.

Cognition Disorders↗

Can drugs cause depression? A review of the evidence.

Drug-induced depressive disorders are classified in the DSM-III-R as organic mood syndrome, depressed type. The ability of certain drugs to cause depression is of clinical relevance because organic mood syndrome is a component of the differential diagnosis of depressive symptoms. Consequently, psychiatric textbooks often provide different lists of drugs thought to be capable of causing depression. Strong evidence supporting the existence of causal associations is often lacking. There is no specific drug for which there is definitive evidence of a causal association with depressive symptoms or depressive disorders. Nevertheless, for a number of drugs, the evidence is suggestive, although not conclusively, of a causal association. Despite this, rational decisions about the continuation or discontinuation of drugs can often be made. In this paper, the literature is reviewed and guidelines are suggested for the management of patients with depressive symptoms which may be related to drugs.

Depressive Disorder↗

The comparative efficacy of trazodone and imipramine in the treatment of depression.

OBJECTIVE: To review published clinical trials comparing the efficacy of trazodone with that of tricyclic antidepressant medication. DATA SOURCES: MEDLINE was searched for relevant articles published from 1983 to 1991. The bibliography of a review article was searched for further references. STUDY SELECTION: In all, 25 clinical trials were found. Six of these met the methodologic assessment criteria (adapted from the McMaster guidelines for the evaluation of clinical trials), which included the stipulation of a score of 18 or more on the Hamilton depression rating scale and a 50% reduction in that score as an outcome measure. DATA EXTRACTION: All six studies compared trazodone with imipramine. Data describing response to the treatments were extracted, and post-hoc power estimates were calculated. The analysis also involved statistical tests of a modified null hypothesis, the generation of confidence intervals (CIs) and a meta-analysis. DATA SYNTHESIS: All the studies found no significant difference in the efficacy of trazodone and imipramine. However, the statistical power of most of them was less than 50% and often less than 10%; thus there was a low probability that differences would be detected. The results of statistical tests of the modified null hypothesis, inspection of the CIs and the results of the meta-analysis all suggested that trazodone, and imipramine are equally efficacious. CONCLUSION: The application of various techniques for the analysis of equivalence data suggests that trazodone and imipramine are of approximately equivalent efficacy. The data are compatible with small differences in efficacy, but the differences are of a magnitude such that they are unlikely to be of clinical significance.

Clinical Trials as Topic↗